INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10568380	
	Filing Date		2006-02-14	
	First Named Inventor	Susan Ashwell		
	Art Unit		1626	
	Examiner Name S		Shameem, Golam M	
	Attorney Docket Numb	er	101064-1P US	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Pat of cited Docu	Releva		Lines where ges or Relev		
	1 .										
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.	<u> </u>	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS	,	Remove	<u>. </u>	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pat of cited Docu	entee or Applicant ument	Releva		Lines where ges or Relev	
/GS/	1	20070010556	A1	2007-01	I-11	Ashwell et al.					
If you wisl	h to a	ldd additional U.S. Publi	ished Ap	plication	n citatio	information i	please click the Add	d button	Add		
		•		FOREIG	GN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	e or V	vhere Rele	or Relevant	T5
/GS/	1	2001098290	wo .		A2	2001-12-27	Pharmacia & Upjoh A.	n S.P.			
/GS/	2	2004063185	wo		A1	2004-07-29	AstraZeneca AB AstraZeneca UK Lii	mited			
/GS/	3	2003029241	wo		A1	2003-04-10	SmithKline Beechal Corporation	m			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

				
Application Number		10568380		
Filing Date		2006-02-14		
First Named Inventor	Susar	Ashwell		
Art Unit		1626		
Examiner Name	Sham	eem, Golam M		
Attorney Docket Number		101064-1P US		

			·					· · · · · · · · · · · · · · · · · · ·	
	/GS/	4	2003028731	wo	A1	2003-04-10	SmithKline Beecham Corporation		
		5	9852558	wo	A1	1998-11-26	Bayer Corporation		. 🗆
		6	2005033102	wo	A2	2005-04-14	Amphora Discovery Corporation		
		7	2006062982	wo .	A2	2006-06-15	Locus Pharmaceuticals	,	
	:	8	2006062984	wo	A2	2006-06-15	Locus Pharmaceuticals Inc		
		9	2001058890	wo	A1	2001-08-16	AstraZeneca AB		
		10	2002030353	wo	A2	2002-04-18	SmithKline Beecham Corporation		
		11	2003029242	wo	A1	2003-04-10	SmithKline Beecham Corporation		
		12	2003104218	wo	A1	2003-12-18	SmithKline Beecham Corporation	·	
		13	2004053087	wo	A2 '	2004-06-24	SmithKline Beecham Corporation		
\	/	14	2005105777	wo	A1	2005-11-10	Pharmacia & Upjohn Company LLC		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10568380			
Filing Date		2006-02-14			
First Named Inventor Susan		n Ashwell			
Art Unit		1626			
Examiner Name Sham		eem, Golam M			
Attorney Docket Number		101064-1P US			

/GS/	15	02070494	wo	A1	2002-09-12	ICOS Corporation					
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Cite Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.											
/GS/	1.	BAXTER et al. Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK -2 inhibitors. Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2817-2822.									
/GS/	2	AstraZeneca PLC, Novel thiophenecarboxamide IKK -2 inhibitors. Expert Opinion on Therapeutic Patents (2005), 15(3), 343-347.									
If you wis	h to ac	dd additional n	on-patent literature do	cument ci	tation informati	ion please click the Add I	button Add				
				EXAMINE	R SIGNATUR	E					
Examiner	Signa	ture /Gola	am Shameem/			Date Considered	08/15/2007				
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										
Standard ST 4 Kind of doo	T.3). ³ F cument	For Japanese pate	ent documents, the indicatio e symbols as indicated on th	n of the year	of the reign of the	r office that issued the docume Emperor must precede the sei dard ST.16 if possible. ⁵ Applie	rial number of the patent doc	ument.			